SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.

MLA

Rothschild, Sacha I., et al. “SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 39, no. 26, Sept. 2021, pp. 2872–80. EBSCOhost, https://doi.org/10.1200/JCO.21.00276.

APA

Rothschild, S. I., Zippelius, A., Eboulet, E. I., Savic Prince, S., Betticher, D., Bettini, A., Früh, M., Joerger, M., Lardinois, D., Gelpke, H., Mauti, L. A., Britschgi, C., Weder, W., Peters, S., Mark, M., Cathomas, R., Ochsenbein, A. F., Janthur, W.-D., Waibel, C., … Pless, M. (2021). SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 39(26), 2872–2880. https://doi.org/10.1200/JCO.21.00276

Chicago

Rothschild, Sacha I, Alfred Zippelius, Eric I Eboulet, Spasenija Savic Prince, Daniel Betticher, Adrienne Bettini, Martin Früh, et al. 2021. “SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 39 (26): 2872–80. doi:10.1200/JCO.21.00276.